CLINICAL-EPIDEMIOLOGICAL CHARACTERISTICS OF A COHORT OF PATIENTS TREATED WITH DORAVIRINE

Gómez de Rueda F.[1], Rendón de Lope L.[1],Cancela Díez B.[2]
[1]Hospital Universitario Virgen Macarena, Sevilla.
[2]Hospital San Agustín, Linares.

4CPS-077

ATC CODE: J05-ANTIVIRAL FOR SYSTEMIC USE

BACKGROUND AND IMPORTANCE

Doravirine is a non-competitive, non-nucleoside reverse transcriptase inhibitor (RTI), used in combination regimens with other antiretrovirals for the treatment of HIV-1 without evidence of resistance to non-nucleoside inhibitors.

AIM AND OBJECTIVES

To describe the clinical-epidemiological characteristics and the clinical and analytical evolution of DORA associated with abacavir/lamivudine (ABC/3TC), dolutegravir (DTG) and rilpivirine (RPV).









Results

36 patients
Age 53,8 years (26-64)

31 5

Treatment	Patients
ABC/3TC+DORA	20
RPV+DORA	9
DTG+DORA	7

77% smokers

7 with alcohol habit

34 stages A2/A3

2 stage B3

At the beginning: 34 patients CV<50 cop/ml; 2 patients CV>10x6 cop/ml

During the study: 34 patients CV<50 cop/ml; 2 patients CV 110-150 cop/ml

CD4-T lymphocyte NORMAL (262-1169/µL)

Creatinine NORMAL (0.9-1.1 mg/dl) except 2 patients (1,13 and 1,29 mg/dl)

Most common side effects*
Diarrhea
Nausea and/or vomiting
Mild headaches

*2 patients reported myalgia, probably related to atorvastatin treatment.

Patients with RPV+DORA came from ABC/3TC+DORA **RPV was replaced due to hypercholesterolemia, liver disorders or intake of PPIs or NSAIDs.**

MATERIAL AND METHODS

To assess the efficacy of DORA, clinical response was analyzed through follow-up consultations and serological tests, measuring viral load (VL), CD4-T lymphocytes, liver profile and renal function.

At 2, 4 and 6 months from the start of treatment.

Viral load | **CD4-T lymphocytes** | **Liver profile** | **Renal function**

CONCLUSION AND RELEVANCE

Doravirine has been shown to be a safe and effective therapeutic alternative for HIV-1 infection, especially in patients with metabolic disorders or interactions with other drugs.

The role of hospital pharmacists

To guarantee adherence to treatment.

To document the most frequent side effects by reporting them to the Local HIV Commission.

REFERENCES AND/OR ACKNOWLEDGEMENTS

AEMPS. Ficha técnica del medicamento. Available en: https://cima.aemps.es/cima/pdfs/es/ft/1181332001/FT_1181332001.pdf

Special thanks to the Infectious Diseases Unit.

Hospital Universitario Virgen Macarena

27th EAHP CONGRESS 22-23-24 MARCH 2023 Lisbon